本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
SHANGHAI, Oct. 24, 2025 /PRNewswire/ -- At 15:00 Beijing Time (09:00 am Berlin Time) on October 20, the "Global Launch Event for Iza-bren (EGFR×HER3 Bispecific ADC) Nasopharyngeal Carcinoma BL-B01D1-303 Research Results" was held at the venue of the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin. eChinaHealth held a forum on progress of nasopharyngeal carcinoma, and Biokin Pharma participated in sharing the research results and reported the Iza bren BL-B01D1-303 research report. The Launch Event focused on the BL-B01D1-303 study (hereinafter: 303 Study) led by Chinese scholars. The study evaluated the efficacy and safety of iza-bren for later-line treatment of recurrent/metastatic nasopharyngeal carcinoma (R/M NPC). Recognized for its "doubled efficacy" outstanding efficacy data and significant clinical importance, the study was selected as a Late-breaking Abstract (LBA) for the Developmental Therapeutics Session at this ESMO Congress and was simultaneously published in The Lancet, fully demonstrating the international academic community's full affirmation of this research[1],[2]. The Launch Event received widespread attention from the global medical community and media. The venue gathered eight authoritative domestic and international media outlets. ESMO official also provided strong support, conducting a live broadcast via its official website and providing replay videos for continuous learning by global doctors, fully showcasing the academic influence and R&D strength of China's innovative drugs on the international stage. The study's Leading Principal Investigator: Professor Li Zhang from Sun Yat-sen University Cancer Center; the 303 Study presenter at the ESMO Congress: Professor Huaqiang Zhou from Sun Yat-sen University Cancer Center; and Dr. Jonathan Cheng, Chief Medical Officer of SystImmune, Inc, attended the Launch Event. They systematically elaborated the key path of iza-bren from biological validation to clinical practice translation and answered questions from Chinese and international media reporters on hot topics related to the research. Scientific Breakthrough and Clinical Value: Iza-bren Achieves Technological Revolution in Delaying and Overcoming Resistance At the beginning of the conference, Professor Li Zhang stated in his speech that the great success of the global first Phase III study of a bispecific ADC for later-line treatment of recurrent/metastatic nasopharyngeal carcinoma is an important milestone of iza-bren and will lead global nasopharyngeal carcinoma treatment into the ADC era. Dr. Jonathan Cheng reviewed the journey of the EGFR×HER3 bispecific ADC from target biological validation to clinical development, and provided a forward-looking perspective on the future clinical application prospects and development path of iza-bren. The innovative design concept of iza-bren is remarkable: The EGFR×HER3 bispecific antibody design adopted by iza-bren is not a simple "1+1" superposition. Compared to single-target ADCs, such bispecific ADCs have more and more significant advantages in design, including higher target specificity, stronger binding capacity to tumor tissues, and lower off-target toxicity to normal tissues, thereby significantly improving therapeutic efficacy. Particularly outstanding is the ability of bispecific ADCs to simultaneously block the initial treatment target and resistance-related targets, effectively delaying or overcoming the emergence of resistance mechanisms, a characteristic difficult to achieve with single-target ADCs. Iza-bren's dual mechanism of action blocks EGFR and HER3 signals to cancer cells, reducing proliferation and survival signals. In addition, upon antibody mediated internalization, iza-bren's therapeutic novel topo-I inhibitor payload (Ed-04) payload is released causing cytotoxic stress that leads to cancer cell death. The drug-to-antibody ratio (DAR) of iza-bren is 8, which helps enhance its bystander effect and improve its killing capacity against tumor tissue cells. Based on the widespread expression of EGFR in various solid tumors, iza-bren is demonstrating significant cross-tumor potential. To date, more than ten registrational Phase III clinical studies have been initiated globally, covering multiple solid tumor areas including lung cancer, breast cancer, esophageal cancer, urothelial carcinoma, and ovarian cancer, including three global multi-center clinical trials, laying a solid foundation for China's innovative drugs to enter the international market. Outstanding Data and Global Debut: iza-bren Doubles Efficacy! Nasopharyngeal Carcinoma Leads Solid Tumor Treatment into the Bispecific ADC Era Professor Huaqiang Zhou provided a systematic and in-depth interpretation of the 303 Study, pointing out that this study is expected to completely reshape the diagnosis and treatment landscape of nasopharyngeal carcinoma in China and even globally. The 303 Study is the world's first Phase III clinical study for later-line treatment of recurrent/metastatic nasopharyngeal carcinoma, providing high-quality evidence-based medicine for later-line treatment in this field. While confirming the significant clinical efficacy of iza-bren, this study also clarified that the objective response rate (ORR) of later-line monotherapy chemotherapy regimens is approximately 30%. Furthermore, this study is also the world's first Phase III clinical trial on a bispecific ADC, marking the official transition of bispecific ADC drugs, represented by iza-bren, from the proof-of-concept stage to the comprehensive clinical validation stage. The study enrolled a total of 386 patients, all of whom had previously received at least two lines of systemic therapy, overall belonging to a heavily pre-treated, high tumor burden population. Over 40% of patients had received ≥3 prior lines of therapy, and nearly 50% of patients had distant organ metastases such as liver, bone, or lung metastases at baseline. In this patient population with significant clinical challenges, iza-bren delivered excellent results, achieving "doubled efficacy" in multiple dimensions compared to the gemcitabine-containing monotherapy chemotherapy regimen! The confirmed Objective Response Rate (cORR) reached 54.6%, significantly higher than 27.0% in the control group, achieving a doubling; subgroup analysis showed that regardless of patient baseline characteristics, iza-bren could bring consistent and stable high response rates. Notably, complete response (CR) cases were observed in the iza-bren group, demonstrating its excellent ability to clear tumor lesions[1],[2]. The median Progression-Free Survival (mPFS) broke through 8 months for the first time, reaching 8.38 months, also doubling compared to 4.34 months in the control group; the results of various pre-specified subgroup analyses were consistent, with hazard ratios (HR) all less than 0.5, indicating that patients with different baseline characteristics can benefit from iza-bren treatment, and the treatment benefit is universal[1],[2]. The risk of disease progression or death was significantly reduced by 56%, the highest reduction reported so far in the field of later-line treatment for recurrent/metastatic nasopharyngeal carcinoma, fully demonstrating the significant advantage of iza-bren in disease control, far exceeding the existing standard treatment level, and significantly enhancing the treatment confidence of clinicians and patients[1],[2]. In terms of safety, iza-bren demonstrated a predictable and manageable safety profile in the 303 Study, with no new safety signals identified. The most common ≥Grade 3 treatment-related adverse events (TRAEs) were primarily hematological toxicities, most of which were transient and relatively simple to manage clinically; the median correction times for neutropenia and thrombocytopenia were 4 days and 5 days, respectively, indicating that its toxic reactions are usually short-lived and easy to recover from, conducive to long-term treatment maintenance and sustained clinical benefit for patients[1],[2]. Professor Huaqiang Zhou quoted a comment from The Lancet: "In the 303 study, iza-bren achieved doubled efficacy compared to chemotherapy, the results are encouraging, ADC will become an important pillar of nasopharyngeal carcinoma treatment."[3] Broad Layout and Global Leadership: From Reshaping Nasopharyngeal Carcinoma Treatment Standards to Pan-Tumor Internationalization Layout Representatives from global media engaged in in-depth exchanges with Professor Li Zhang, Professor Huaqiang Zhou, and Dr. Jonathan Cheng on various aspects, including the global leadership of this research, the advantages of iza-bren's mechanism of action (MOA), and the company's international strategic layout. The success of the 303 Study has significant clinical importance and historical value, providing key reference for clinical research and diagnosis and treatment practice in the global nasopharyngeal carcinoma field. As the first-in-class EGFR × HER3 bispecific antibody-drug conjugate, iza-bren, with its innovative molecular structure design and dual-target inhibition mechanism, has achieved overwhelming efficacy data. Multiple clinical studies, including the 303 Study, have shown excellent efficacy data, fully validating the advantages of its mechanism of action. At this ESMO Congress, iza-bren also announced for the first time its treatment results in Western solid tumor patients. This validates its cross-racial, cross-tumor treatment potential, injecting strong momentum into the exploration of iza-bren in pan-tumors. "In the entire field of oncology treatment research, iza-bren has clearly become a star, attracting the attention of scholars, patients, and media whenever it appears," Professor Li Zhang said. Research on iza-bren within the pan-cancer scope is continuing to deepen. Recently, the triggering of the first phase of the collaboration agreement between Bristol Myers Squibb and Biokin Pharma was triggered due to the IZABRIGHT-Breast 01 study reaching an important milestone. Driven by the synergy of domestic and international innovative companies, the clinical research of iza-bren is being efficiently advanced, and its application will be further expanded in multiple tumor types including breast cancer and bladder cancer in the future. Charting the Blueprint and Future Outlook: Chinese Innovative Drugs Contribute to the Global Anti-Cancer Cause For patients, the success of the 303 Study provides them with an efficient new treatment option, offering new hope to patients who originally had "no drugs available." Particularly valuable is that iza-bren enabled some patients to achieve complete response, which is extremely rare in later-line treatment, meaning the possibility of touching cancer cure. For clinical practice, the 303 Study is the first to establish a new standard for later-line treatment of nasopharyngeal carcinoma through a high-standard randomized controlled trial, with significant therapeutic effects and good safety, solving a long-standing clinical pain point. For industry development, the bispecific ADC iza-bren reflects the successful strategic transformation of China's innovative drug development from "fast-follow" to "first-in-class," proving that China's independent innovation platforms, innovative drugs, and innovative research will contribute wisdom to global medical development. On September 5, 2025, the CDE official website announced that the iza-bren nasopharyngeal carcinoma indication was officially included in the priority review, meaning that this innovative therapy will be accelerated to benefit Chinese patients first. With the advancement of the priority review, the expansion of global development, and the exploration of pan-cancers, iza-bren is expected to become another milestone drug in the history of tumor treatment, bringing new treatment options to global tumor patients. Reference: [1]. Huaqiang Zhou, et al. Iza-Bren (BL-B01D1), an EGFR×HER3 bispecific antibody-drug conjugate, versus physician's choice of chemotherapy in heavily pretreated recurrent/metastatic nasopharyngeal carcinoma: A randomized, open-label, multicenter, phase III, pivotal study (BL-B01D1-303). 2025 ESMO, LBA 35. [2]. Yang, Yunpeng et al. Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China[J]. The Lancet, 2025. [3]. CHAN A T C, HUI E P, MA B B Y. The arrival of antibody drug conjugates in nasopharyngeal cancer[J]. The LancetThe Lancet, 2025. About iza-bren iza-bren (BL-B01D1), a bispecific antibody-drug conjugate (ADC) that targets both EGFR and HER3, which are highly expressed in various epithelial cancers and are known to be associated with cancer cell proliferation and survival. Iza-bren's dual mechanism of action blocks EGFR and HER3 signals to cancer cells, reducing proliferation and survival signals. In addition, upon antibody mediated internalization, iza-bren's therapeutic novel topo-I inhibitor payload (Ed-04) payload is released causing cytotoxic stress that leads to cancer cell death. About Biokin Pharma Founded in 1996, Biokin, after 26 years of steady growth, has become a biopharmaceutical company integrating the full life cycle of new drug and pharmaceutical product development from new drug research and development to production and marketing. Biokin has built a proprietary and fully integrated biological drug development platform in China and the United States, a world-leading tumor antibody drug development platform and research pipeline and owns a comprehensive and well-preserved intellectual property portfolio. Biokin operates a nationally certified technological center and is an inaugural member of the Chinese Pediatric Medicine R&D and Industrialization Alliance. Biokin has won numerous awards, including recognition as "China's Best Industrial Company in Pharmaceutical R&D Product Line." Biokin is a biopharmaceutical company, integrating drug research and development, production, and marketing. Biokin owns R&D centers in China and the United States (US: Systimmune, Inc.; China: Baili Pharmaceutical and Baili-Bio Pharmaceutical, etc.), a biological drug and antibody conjugated drug production facility (Baili-Bio Pharmaceutical), two pharmaceutical formulation facilities (Baili Pharmaceutical and Guorui Pharmaceutical), one active pharmaceutical ingredient production facility (Jingxi Pharmaceutical), one chemical intermediate manufacturer (Hayate Technology) and two pharmaceutical marketing companies (Biokin and Lhasa Xinbo). About SystImmune, Inc. SystImmune is a clinical-stage biopharmaceutical company located in Redmond, WA and Princeton, NJ. It specializes in developing innovative cancer treatments using its established drug development platforms, focusing on bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs). SystImmune has several assets in various stages of clinical trials for solid tumor and hematologic indications. Alongside ongoing clinical trials, SystImmune has a robust preclinical pipeline of potential cancer therapeutics in the discovery or IND-enabling stages, representing cutting-edge biologics development. Forward-Looking Statements Any research and development information provided by eChinaHealth is intended for general information purposes only. Such information is not intended to provide complete medical information. We do not offer patient-specific treatment advice and if you have medical conditions, please see your medical doctor or healthcare provider. This press release may contain forward-looking statements with the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, which reflects the expectations regarding the company's goals, strategies, results of operations, performance, business prospects, and opportunities, including but not limited to the ability to gain Investigational New Drug status for the resulting new product and the ability to develop a successful formulation. Terms such as "anticipates," "believes," "expects," "estimates," "could," "intends," "may," "plans," "potential," "projects," "will," "would" and other similar expressions, or the negative of these terms, are generally indicative of forward-looking statements. While eChinaHealth, Inc. believes that expectations expressed in the forward-looking statements are based on the company's reasonable assumptions and beliefs in light of the information available to the company at the time such statements are made, it cannot give assurance that such forward-looking statements will prove to have been correct. Such forward-looking statements are not fact and are subject to uncertainties and other factors that could cause actual results to differ materially from such statements. We undertake no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
BRUSSELS, Oct. 24, 2025 /PRNewswire/ -- Results for the first nine months of 2025 Financial highlights Record deposit levels, solid business performance and improved operating margin In the first three quarters of 2025, Euroclear has achieved solid financial performance and demonstrated sustained growth in most business lines coupled with disciplined cost management. Underlying business income increased by 7% year-on-year to reach €1.4 billion, driven by record-high deposit levels, resilient settlement activity, strong ETF flows and solid international fixed income volumes. As anticipated, interest and banking income continues to decrease (-10%) to approx. €800 million, mainly due to lower interest rates. Nevertheless, net interest earnings exceeded expectations, supported by stable USD interest rates and higher balances. After adjusting for non-recurring items, operating expenses increased by €31 million (+3%) to €1,021 million. Cost mitigation measures continue to progress and helped offset inflationary impacts and increased wage-related costs. Inversis, in which Euroclear has held a 49% stake since March 2025, contributed €7 million to the share of results, outperforming expectations. Initial synergies were realised with Inversis transferring its international settlement and custody service to Euroclear Bank. As planned, Euroclear will acquire the remaining 51% in the coming years to accelerate the growth of its funds offering and expand its presence in Southern Europe. As result of the positive operating leverage, business income operating margin continues to improve to 27.4% (+3.4% percentage points), reflecting continued growth in core activities and effective cost control. Resulting adjusted net profit remains stable at €878 million. Adjusted Earnings Per Share is €27.91. Euroclear Group's capital position remains very strong, comfortably above regulatory requirements with a Common Equity Tier 1 capital ratio of around 61%2. The impacts of the Russian sanctions are detailed in the last section of this press release. Euroclear financial performance Q3 2025 Valerie Urbain, Chief Executive Officer of Euroclear, commented: "Our performance demonstrates the continued strength and resilience of our business. We delivered solid growth in our core activities, with underlying business income up 7% year-on-year to €1.4 billion and our operating margin improving to 27.4%. In the nine first months of 2025, our systems seamlessly processed 267 million transactions worth over €1 quadrillion. This represents a year-on-year increase of 20% and a new record confirming Euroclear's systemic role at the heart of the global capital markets. In Europe, we continue to implement our vision for a true Savings and Investments Union – one that delivers tangible benefits to issuers, investors and all users through deepening liquidity pools, ensuring systems are interoperable and asset classes are fungible. Euroclear's plan is clear: providing a single point of access across all financial asset classes to the 27 Member States and the UK. This commitment is supported by innovative projects to develop a modern and interconnected market infrastructure, most recently illustrated by our collaboration with Banque de France to tokenise short-term debt (NEU CP) on our DLT platform. We are aware that the European Commission is working on a proposal to provide Ukraine with a Reparations Loan. We expect to receive further information on the envisaged mechanism and will continue to engage with decision-makers. Any proposal should respect international law and internationally accepted legal principles underpinning Western economies, and protect the interests of Euroclear and its stakeholders." Business performance The key operating metrics (end of period unless stated otherwise) demonstrate an excellent business performance during the period. End Q3 2024 End Q3 2025 YoY evolution 3-year CAGR Assets under custody €40 trillion €42.5 trillion +5 % +7 % Number of transactions 243 million 267 million +10 % +5 % Turnover €850 trillion €1,008 trillion +19 % +8 % Fund assets undercustody €3.4 trillion €3.8 trillion +10 % +10 % Collateral Highway €1.9 trillion €2 trillion +5 % +2 % Underlying cash deposits(YTD average) €22.4 billion €23.9 billion +7 % -2 % Strong market activity boosted Euroclear's operating metrics in the first nine months of 2025, with assets under custody exceeding €42 trillion for the first time, continuing twelve quarters of growth. Turnover rose nearly 20% from Q3 2024 to over €1 quadrillion by the end of September 2025, driven by solid growth in most European fixed income markets and Eurobonds, as well as increased settlement activity amid heightened market volatility and macroeconomic uncertainty. Funds depot reached a record €3.8 trillion, supported by the success of ETFs and strong stock valuations. Daily average outstanding amounts on the Collateral Highway, approx. €2 trillion, remain near peak levels thanks to higher OTCD and repo market activity. Recent business milestones Tokenising short-term debt in France Building upon a robust legacy of innovation, Banque de France and Euroclear have announced the launch of a project to tokenise Negotiable European Commercial Paper (NEU CP), with the objective of modernising short-term debt markets through distributed ledger technology (DLT). The pilot phase aims to implement an interconnected wholesale Central Bank Digital Currency (CBDC) leveraging the ECB's TARGET services. Euroclear's DLT-based platform will be designed with interoperability at its core, supporting seamless integration across financial infrastructures. Digitising the Eurobond market Euroclear Bank and Clearstream, the two International Central Securities Depositories (ICSDs), have announced the further digitisation of the Eurobond market, the world's third-largest debt market with a current value of €14 trillion. As from 2026, the two ICSDs will support the issuance of Eurobonds in dematerialised form, eliminating the need for paper certificates and supporting the adoption of automation and new technologies across the entire Eurobond lifecycle. To further reduce fragmentation, the ICSDs have co-developed a new Issuance & Processing Taxonomy as an industry-wide, technology-agnostic standard. Bank of China (Hong Kong) Limited joins Eurobond depository network The two International Central Securities Depositories have also appointed Bank of China (Hong Kong) Limited (BOCHK) as common depository, safekeeper and service provider for international securities, also known as Eurobonds. They act jointly as the central hub of ISIN allocation, issuance and deposit for Eurobonds. As a result, issuers benefit from greater investor reach by leveraging the ICSDs' international client bases and multi-currency model. This move allows an even closer connection to the APAC issuance and investor communities for a more efficient servicing of the securities throughout their lifecycle. Freedom of choice for settlement in Belgium, France and the Netherlands Euroclear continues to defend open market access and client choice of settlement location in Europe. Following Euronext's unilateral decision to designate its own Milan-based venue for the settlement of equity and ETF/ETP trades for its exchanges in Amsterdam, Brussels and Paris as from September 2026, Euroclear has applied as alternative CSD to allow clients to settle their trades as they do today. Euroclear is confident it is fulfilling the requirements to be a settlement venue for these markets. Expanding our funds ecosystem in the UK, France and Portugal In the past months, Euroclear has announced a number of significant funds-related partnerships: Euroclear has entered a strategic agreement with Aegon UK, one of the leading retirement and investment providers in the United Kingdom, to deliver its end-to-end funds distribution solution, through Euroclear FundsPlace®. Aegon UK will benefit from an integrated suite of services, enabling streamlined access to mutual funds through a single platform that covers distribution, order routing, settlement, asset servicing, and data services. Bourse Direct, a major French player in online brokerage, has become the first retail broker to establish a direct connection with Euroclear Bank, allowing it to streamline ETF settlement and offer its clients access to a wide range of ETFs, supported by Euroclear's secure and efficient infrastructure. Novo Banco, Portugal's fourth-largest bank, has selected Euroclear FundsPlace® as its exclusive provider for fund distribution services. Euroclear will manage platform services and automate trailer fee collection for Novo Banco's mutual fund depot. The move will reduce complexity, bring greater transparency and improve efficiency across the bank's distribution model. Russian sanctions impacts Financial impacts of the Russian assets Interest earnings from Russian sanctioned assets were €3.9 billion, a 25% year-on-year decrease due to gradual rate cuts. Future interest earnings will continue to evolve in line with future policy rates. As required by the EU windfall contribution regulation, Euroclear provisioned €2.6 billion as windfall contribution for YTD 2025, of which €1.6 billion has been paid to the European Commission in July 2025. A second payment for 2025 is expected in early 2026. The Russian sanctions and countermeasures resulted in direct costs of €82 million and a loss of business income of €25 million year-to-date. Euroclear Russian sanctions Q3 2025 Update on Russian sanctions and countermeasures Russia's invasion of Ukraine in February 2022 resulted in market-wide application of international sanctions. Euroclear considers the application of international sanctions as a key obligation. Therefore, well established processes are in place which have allowed the group to implement the sanctions while maintaining our normal course of business. As a result of the sanctions, blocked coupon payments and redemptions owed to sanctioned entities continue to accumulate on Euroclear Bank's balance sheet. At the end of September 2025, Euroclear Bank's balance sheet totalled €227 billion, of which €193 billion relate to sanctioned Russian assets. In line with Euroclear's risk appetite and policies and as expected by the EU Capital Requirements Regulation, Euroclear's cash balances are re-invested to minimise risk and capital requirements. In May 2024, the European Commission has adopted a new regulation about a windfall contribution applicable to CSDs holding Russian Central Bank assets with a total value of more than €1 million. The profits generated by the reinvestment of these sanctioned amounts dating from 15 February 2024 onwards are required to be contributed to the European Fund for Ukraine. To date, Euroclear contributed approx. €5 billion to the European Fund for Ukraine. Euroclear continues to act prudently and to strengthen its capital by retaining the remainder of the Russian sanction related profits as a buffer against current and future risks. Euroclear is focused on minimising potential legal, financial, and operational risks that may arise for itself and its clients, while complying with its obligations. As a direct consequence of the sanctions and countermeasures, Euroclear faces multiple proceedings in Russian courts. Since Russia considers international sanctions against public order, Russian claimants initiated legal proceedings aiming mainly to access assets blocked in Euroclear Bank's books, by claiming an equivalent amount in Russian Ruble and enforcing their claim in Russia. Despite all legal actions taken by Euroclear and the considerable resources mobilised, the probability of unfavourable rulings in Russian courts is high since Russia does not recognise the international sanctions. Annexes Euroclear cash balances Q3 2025 Euroclear Bank and Euroclear Holding are the two group issuing entities. The Q3 2025 summary income statements and financial positions for both entities are shown below. Euroclear income statements Q3 2025 Figures as of 30 September 2025 About EuroclearEuroclear group is the financial industry's trusted provider of post trade services. Guided by its purpose, Euroclear innovates to bring safety, efficiency, and connections to financial markets for sustainable economic growth. Euroclear provides settlement and custody of domestic and cross-border securities for bonds, equities and derivatives, and investment funds. As a proven, resilient capital market infrastructure, Euroclear is committed to delivering risk-mitigation, automation, and efficiency at scale for its global client franchise. The Euroclear group comprises Euroclear Bank, the International CSD, as well as Euroclear Belgium, Euroclear Finland, Euroclear France, Euroclear Nederland, Euroclear Sweden and Euroclear UK & International. 1 Post 10:1 share split as of July 1, 20252 Based on estimated RWA of around €14.2 billion (of which around €6 billion of RWA are related to Russian assets) and CET1 capital of around €8.7 billion Contact: Pascal Brabant / pascal.brabant@euroclear.com / +32 475 78 36 62
BEIJING, Oct. 24, 2025 /PRNewswire/ -- A report from China Daily Global Mining Industry In Accelerated Transformation By China Daily Nearly 450 billion yuan ($63 billion) has been invested in mineral exploration and 150 new mineral deposits have been discovered nationwide during the 14th Five-Year Plan (2021-25) period, the Ministry of Natural Resources announced on Thursday. According to the China Mineral Resources (2025) report unveiled by the ministry at the 27th China Mining Conference and Exhibition, which opened in Tianjin on Wednesday, China's investment in geological exploration amounted to nearly 116 billion yuan last year, marking four consecutive years of growth. Last year, China's production of 10 types of nonferrous metals continued to increase, while the output of "energy minerals" such as coal, crude oil and natural gas reached a record high. "Over the course of the 14th Five-Year Plan period, more than 160,000 hectares of abandoned mines were rehabilitated, and China's geological and mining relations were further expanded," Xu Dachun, vice-minister of natural resources, said. Xu, who is also director of China Geological Survey, an institution under the Ministry of Natural Resources, said that cooperation agreements were signed with over 70 countries and international organizations, while 30 bilateral and multilateral cooperation platforms were established with countries involved in the Belt and Road Initiative and more than 100 cooperative projects were organized to implement international large-scale scientific plans. These efforts "provided high-quality public goods for global sustainable development of resources and the environment", he added. According to the report, China made new achievements last year in promoting green development in mining and actively implementing the United Nations 2030 Agenda for Sustainable Development. China has fully implemented green exploration, promoted the upgrading and application of technology, and reached a globally advanced level in the comprehensive utilization of mineral resources, it said. At the conference, representatives of nearly 500 domestic and international enterprises from 42 nations discussed cooperation projects and cutting-edge mining tech, sharing new opportunities for international collaboration. Phumzile Mgcina, South Africa's deputy minister of mineral and petroleum resources, welcomed the growing presence of Chinese-owned mining companies in her country, noting that such investments have contributed to economic growth, job creation, knowledge exchange and continued partnership. Isabella Chirchir, mining commissioner at Namibia's Ministry of Industries, Mines and Energy, expressed the hope for increased exchanges with China, especially to learn and adopt Chinese technical expertise in mining and related fields. China has progressed a lot in terms of technology, and has even found green energy solutions for mines, she said, adding that Namibia will look forward to opportunities to learn from China and implement such technologies. Wang Xu, Tianjin's executive vice-mayor and member of the Standing Committee of the Communist Party of China Tianjin Municipal Committee, said the city thrives because of the sea, with Tianjin Port connecting to over 500 ports in more than 180 countries and regions. The port ranks among top 10 globally in terms of cargo export volume, Wang said. "Tianjin is willing to work together with all parties, taking this cross-industry conference as an opportunity to further enhance cooperation and achieve mutual success," he added. Chen Yijun contributed to this story.
Transforming the Financial Services Industry with IOWN® Infrastructure HONG KONG, Oct. 24, 2025 /PRNewswire/ -- NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation, hereafter "NTT DOCOMO BUSINESS") and its Hong Kong subsidiary, NTT Com Asia, today announced the launch of the "APN InterLink" service in Hong Kong for financial institutions starting November 1, 2025, leveraging All-Photonic Network (APN) ※1 technology in support of the IOWN®※2 initiative. Commercially deployed in Hong Kong, one of the leading Asia financial hubs, the new service leverages ultra-low latency photonics-based connectivity to address the evolving digital needs of the financial sector, especially for latency-sensitive trading, algorithmic trading※3, proximity market data access and real-time transaction. Looking ahead, NTT DOCOMO BUSINESS and NTT Com Asia plan to expand the deployment of IOWN® APN on the Asia Submarine-cable Express (ASE), which connects Tokyo and Hong Kong, to enable seamless collaboration between major financial centers. 1.Background The financial industry is experiencing rapid digital transformation, driving the need for faster and more sophisticated transactions. Algorithmic trading and other latency-sensitive trading, such as High Frequency Trading (HFT), as well as real-time transaction, are on the rise, making ultra-low latency networks essential for financial institutions to maintain a competitive edge—where even milliseconds can impact trading outcomes. With APN InterLink, financial institutions can accelerate their digital transformation and strengthen their foundation for innovation, including collaborative development and AI-driven initiatives. For mission-critical operations, robust disaster recovery systems are vital to ensure business continuity in the face of severe disruptions. By leveraging IOWN® APN, organizations can achieve efficient, seamless data transmission between geographically distributed sites, significantly enhancing the reliability and operational efficiency of large-scale disaster countermeasures. 2. Service Overview APN InterLink offers the following connectivity solutions for the financial services industry: NTT DOCOMO BUSINESS and NTT Com Asia launch “APN InterLink” service in Hong Kong, transforming the financial services industry with IOWN® infrastructure APN Connection between Data Centers (APN DCLink):The interconnection between NTT Com Asia's Financial Data Center and Tai Po Data Center via APN delivers an ultra-low latency network. With the Financial Data Center is located in close proximity to the Hong Kong Stock Exchange (HKEX), the interconnection ensures optimal performance for mission-critical financial operations such as latency-sensitive trading and real-time transaction processing. APN DCLink - APN Connection between Data Centers Connection between Any Locations (APN DedicatedLink):APN DedicatedLink enables seamless connections between any customer facilities or data centers within Hong Kong. Customers can connect their sites to the FDC and TPDC, achieving ultra-low latency access to the HKEX. APN DedicatedLink - Connection between Any Locations via APN 3. Future Developments To meet the growing demand for low-latency connectivity between Japan and Hong Kong SAR, NTT DOCOMO BUSINESS offers "docomo business APN Plus powered by IOWN®" ※4 (hereafter "docomo business APN Plus") in Japan, whereas NTT Com Asia offers "APN InterLink" in Hong Kong, enabling high-speed access in both markets. NTT DOCOMO BUSINESS and NTT Com Asia plan to further expand APN deployment on the ASE cable connecting Tokyo and Hong Kong, and establish IOWN® APN hubs throughout Asia. This initiative will facilitate seamless collaboration between major financial centers and accelerating digital transformation in the financial industry. 4. Endorsements "NTT DOCOMO Business is providing the IOWN® APN service "docomo business APN Plus" in Japan, which has been well received by many customers. We are actively working to connect "APN InterLink", set for commercial deployment in Hong Kong SAR, with Japan's "docomo business APN Plus" to deliver the service globally. Through this initiative, we aim to further support our customers' mission-critical applications and business operations. "— Hisashi Fujishima, Senior Executive Officer, Head of Platform Services Division, NTT DOCOMO BUSINESS "We are pleased to launch APN InterLink in Hong Kong, one of the world's leading financial hubs. Leveraging the latest IOWN® technology, we are committed to building next-generation infrastructure for the financial industry."— Daisuke Kuroda, CEO, NTT Com Asia Ltd. 5. Roles of Each Company NTT DOCOMO BUSINESS: Provides the APN service "docomo business APN Plus", and manages sales operations in Japan.NTT Com Asia: Provides the APN service "APN InterLink", and manages sales operations in Hong Kong. 6. Pricing and Application For pricing and application details, please contact the sales representatives at NTT DOCOMO BUSINESS or NTT Com Asia. 7. About IOWN APN IOWN®, a groundbreaking initiative with the mission to revolutionizing network architecture and smart infrastructure, is led by NTT Group and IOWN Global Forum which comprises over 170 member organizations from 19 countries from leaders in telecommunications, cloud computing, semiconductors. At its core is the APN, which replaces conventional electronic transmission with optical communication and software integration. This paradigm shift leverages high capacity, ultra low-latency and energy-efficient photonic-based connectivity to enable transformative capabilities across industries — fulfilling ESG commitments and empowering real-time data processing, intelligent automation, and sustainable digital transformation. NTT Communications Corporation changed its name to NTT DOCOMO BUSINESS, Inc. on July 1, 2025. As an Industrial and Regional DX Platformer that drives digital transformation across industries and communities, we are enabling the development of a decentralized, autonomous, and collaborative society where businesses and communities can thrive sustainably. Our mission is to unlock new value and help create prosperity for all. ※1：APN: An all-photonics network introducing photonics-based technology to everything from networks to terminals. ※2：IOWN®: A network and information processing platform utilizing photonics and information processing technologies to realize a smart society. "IOWN®" is a trademark or registered trademark of NTT Corporation. ※3：Algorithmic trading refers to trading in which computers automatically determine the timing and quantity of stock orders and repeatedly place them. ※4：docomo business APN Plus powered by IOWN®: A high-capacity, low-latency, stable network service based on the IOWN® initiative. *docomo business APN Plus is a trademark pending registration by NTT DOCOMO BUSINESS. About NTT Com Asia As part of the NTT Group, a leading global technology company, NTT Com Asia is committed to building a smart and sustainable world through innovation. We empower businesses to accelerate their digital and AI journeys by unlocking the full potential of data. From smart digital infrastructure, technology services to leading-edge AI solutions, we enable organizations to navigate the evolving challenges of a data-centric world. For more information, please visit: www.ntt.com.hk
BEIJING, Oct. 24, 2025 /PRNewswire/ -- A news report from chinadaily.com.cn City makes significant progress in building application scenarios for eco-friendly and low-carbon advancements. [Photo/VCG] The year 2025 marks the 20th anniversary of the "Two Mountains Theory", a concept that stresses clear waters and lush mountains are invaluable assets, highlighting the crucial role of green development in China. Shanghai, long at the frontier of reform and transformation in the country, has reported outstanding results in its green transition efforts. According to Qiu Wenjin, deputy director of the Shanghai Development and Reform Commission, who participated in the National Ecology Day events in Shanghai on Aug 15, the city has made significant progress in building application scenarios for green and low-carbon advancements, driving breakthroughs in green and low-carbon technologies and the development of emerging green and low-carbon industries. As of June, new energy vehicles, hydrogen energy, energy conservation and environmental protection had become new engines for the economy. In the construction sector, the city has constructed green buildings totaling 437 million square meters and ultralow energy buildings totaling 17 million sq m. In transportation, over 1.8 million NEVs have been sold. Additionally, a total of 1.05 million charging stations and 254 battery swap stations have been built. A slew of policies for different industries have been introduced in recent years to encourage the green and low-carbon development of businesses. With its low-carbon development strategy, Shanghai has become a hotbed for many foreign enterprises pursuing green initiatives. With the introduction of a series of green policies and the continuous optimization of the business environment, an increasing number of global investors are expanding their low-carbon and sustainability investments, leveraging their expertise to support Shanghai's transformation. New cornerstone The inauguration of German automotive supplier ZF Group's auto parts remanufacturing center has set a green benchmark for the industry in the Asia-Pacific region. Relocated from downtown, the new center at the Yangshan Free Trade Zone in Shanghai's Lin-gang Special Area offers a 40 percent increase in production space. This allows ZF to develop a wider array of products to meet rising domestic demand and expand its reach into key Asia-Pacific markets, including Southeast Asia, Japan and South Korea. Plans are underway to scale up production with new offerings, such as automotive control arms, air pumps, and components for NEVs, in addition to the products such as automatic transmissions, valve bodies and electric steering systems it makes. The center also benefits from the unique advantages of the Yangshan zone, such as streamlined bonded maintenance services and overseas licensing support, allowing seamless cross-border operations for the group. As the operator of this cutting-edge hub, ZF brings in a century of expertise and global influence. Founded in 1915, the Fortune Global 500 company ranks as the world's second-largest auto parts supplier and is a global leader in passenger car chassis technology and commercial vehicle components, as well as industrial products. In 2024, its global revenue reached 41.4 billion euros ($48 billion). ZF has connections with China dating back to its market entry in 1980. The company has 30 years of dedicated development in Shanghai, including the establishment of a manufacturing plant in 1995. Today, the group is deeply rooted in China, with its Asia-Pacific headquarters in Shanghai, and five large research and development centers and around 50 factories located across 26 cities. In 2024, ZF sales in Shanghai were worth approximately 23 billion yuan ($3.2 billion). Remanufacturing is one of the cornerstones of ZF's future strategy, integral to both its after-sales market expansion and sustainability goals. With 60 years of experience in the field, ZF operates 20 remanufacturing facilities across 11 countries. In China it has a remanufacturing presence that spans a decade, with the new Shanghai hub joining several smaller facilities. Aligned with the national push for dual-carbon goals — China has pledged to peak carbon dioxide emissions before 2030 and achieve carbon neutrality before 2060 — sustainability is embedded in ZF's business strategy. "Out of 17 core targets of the United Nations' 2030 Sustainable Development Goals, ZF contributes to eight," said Du Xing, head of ZF's sustainability in the Asia-Pacific region. These targets include quality education; affordable and clean energy; decent work and economic growth; industry, innovation and infrastructure; sustainable cities and communities; responsible consumption and production; climate action and partnerships for the goals. ZF's sustainability roadmap aligns with China's dual-carbon goals and circular economy plans. "Our long-term vision is to achieve climate neutrality across the whole value chain by 2040," said Du. "By 2030, we aim to reduce absolute carbon emissions in our own operations by 80 percent compared to 2019 and decrease upstream and downstream carbon emission intensity by 40 percent." Concrete actions are underway. In China, more than 100 energy-saving projects are being executed this year, aiming for savings of 12,000 megawatt-hours. Shanghai alone will see over 30 projects saving 3,800 MWh. For instance, an upgrade to the quenching process at the group's Jiading electric steering plant will cut annual electricity use by over 360,000 kWh. Green energy adoption is another focus. "Starting this year, all ZF factories worldwide will run on 100 percent renewable electricity," Du said. As of 2024, 15 facilities in China, including three large Shanghai plants, had achieved this. Additionally, ZF's long-term green steel supply deal with Swedish company Stegra will cut 475,000 metric tons of carbon dioxide annually, with similar partnerships being forged with Chinese low-carbon and green steel producers. China's promotion of the circular economy and green energy presents vast opportunities, particularly in the NEV sector, which has increased domestic brands' market share. "As a leading auto parts supplier, ZF embraces this trend, unlocking greater market scale and business potential," Du said. "We hope China will introduce more detailed laws, regulations and standards to support healthy industry growth, building on existing circular economy plans," he added. Aiding transition SKF, the Swedish high-end bearing manufacturer, has been at the forefront of green development and is dedicated to helping businesses transition to a clean, responsible, net-zero, and fully circular future in China. Shanghai is deemed a crucial hub for advancing SKF's mission in achieving these goals, according to Wang Hui, president of SKF China and Northeast Asia. "We are committed to 'fighting friction' to move the world forward," said Wang. "By 'fighting friction', we mean advancing new technologies to enhance the operational efficiency of machines. 'Move the world forward' reflects our long-term vision, which goes beyond business to seek overall societal enhancement. "Green and sustainable development is no longer an option; it is the core of our value chain, from product design and production to supply chain development and even our business model. We are transforming from a bearing supplier to a service provider, helping our clients become more energy-efficient," said Wang. Over the past few years, SKF has made significant progress in its green transition in China. All its wholly-owned manufacturing sites, including those in Shanghai, Ningbo in Zhejiang province and Dalian in Liaoning province, are powered entirely by renewable electricity. SKF China has also implemented a smart carbon emissions management system to monitor the status of every piece of equipment, reducing carbon emissions by 60 percent in 2024 compared to 2023, according to Wang. Shanghai, home to the headquarters of SKF China and Northeast Asia, has taken on more responsibilities and made strides in promoting SKF China's sustainable development, according to Wang. The city boasts a robust manufacturing foundation, a rich talent pool and forward-looking policy support, all of which have laid the groundwork for SKF to produce green products and develop green factories. Moreover, these factors have assisted the development of recycling services, including remanufacturing and lubrication management. According to Wang, the concept of life cycle management of bearings, covering design, production, supply chain management, reuse and remanufacturing, was first applied in Shanghai. This development is now a key case study promoted in the city. Additionally, hydrogen-powered trucks, which produce zero emissions, have been introduced at SKF's Northeast Asia distribution center in Shanghai. According to the company, this initiative has reduced annual carbon emissions by 60 percent. SKF's ceramic bearing was also developed in Shanghai for global markets. In the coming years, SKF will continue to leverage its expertise to support the sustainable development of Shanghai and China. It will continue to promote its localization strategy in the country and strengthen collaboration with its clients in Shanghai, including those in steel production, wind power, aviation and semiconductors, to develop tailored solutions that address local demands and emerging challenges. The company has also planned a SEK 3 billion ($321 million) decarbonization investment to phase out its own fossil gas use globally. "Founded in Sweden in 1907, SKF has become deeply embedded in the Chinese market. Our offerings, including bearings, seals, lubrication management, condition monitoring and related services, are instrumental in ensuring the efficient operation of over 40 industries, such as railways, new energy and aviation. We are keen to practice sustainability with our local partners," said Wang. Sustainability upgrade BASF is celebrating its 140th anniversary in China this year. With its China headquarters in Shanghai, BASF has made strides in promoting innovative and sustainable development across the nation, contributing to China's green transition. Apart from supplying products with sustainability attributes, especially in areas where customer demand is rapidly growing, the company is contributing to a sustainability upgrade across the value chain in China, which spans R&D, operations, supply chains and product innovations. "BASF is committed to supporting the green transformation of China's industrial ecosystem. We do this by co-creating sustainable solutions with local partners, driving open innovation through industry-academia collaboration, and building low-carbon supply chains to enable the sustainable development of our customer industries," said Jeffrey Lou, president and chairman of BASF Greater China. At the 2024 Shanghai International Carbon Neutrality Expo, BASF showcased recyclable paper cups developed in collaboration with its partners. These cups, featuring water-based barrier coatings, can be directly recycled in paper mills, thereby reducing carbon emissions and enhancing environmental protection. Guided by the Shanghai Foreign Investment Association, BASF and its partners launched an alliance to promote the recycling of paper cups, inviting more partners to join efforts to optimize resources, support a circular economy, and reduce carbon emissions. Aiming to pioneer future innovations, BASF China has formed close partnerships with local academic institutions to capture emerging trends. BASF has collaborated with the Yangtze River Delta Physics Research Center and Beijing Welion New Energy Technology to develop a concept solid-state battery pack for e-mobility applications. This advanced battery design incorporates more than 20 BASF material solutions to tackle key challenges such as weight, thermal management, safety and sustainability, according to the company. In line with its global commitment to achieve net-zero greenhouse gas emissions by 2050, BASF has played a role in shaping industry standards in China. The company contributed to the development of the Product Carbon Footprint Guideline through the global chemical industry initiative Together for Sustainability, promoting transparency across the supply chain. According to BASF, China — the world's largest chemical market — is shifting toward a development model that emphasizes quality and sustainability. This transformation is unlocking opportunities across emerging sectors such as new mobility, the artificial intelligence industry and renewable energy, as well as industries including smart appliances, energy-efficient buildings and sustainable agriculture. Looking ahead, BASF remains committed to embracing the circular economy and deepening its contribution to China's green transformation. The company says its purpose is to "create chemistry for a sustainable future". BASF believes that sustainability and circularity are not just trends — they are the future.
Joget AI Agent Builder enables teams across every department to create goal-driven agents that execute autonomously, yet remain governed by human insight. COLUMBIA, Md., Oct. 24, 2025 /PRNewswire/ -- Joget Inc., a global innovator in AI-powered open-source application development platforms, today announced the release of Joget AI Agent Builder, the latest addition to Joget Intelligence, the company's integrated AI suite within the newly launched Joget DX 9 platform. Joget envisions a new era of enterprise transformation where people and AI collaborate to proactively create, refine, deploy, and manage applications, multi-step tasks, and end-to-end workflows. With Joget AI Agent Builder, teams—technical or non-technical—can create, test, and deploy intelligent agents that act on your behalf, handling real business tasks from HR onboarding to customer support and supply chain optimization, without writing a single line of code. Built for Business, Designed for Everyone Joget AI Agent Builder puts the power of intelligent automation directly in the hands of the people who know the work best. HR teams can automate onboarding follow-ups, customer service reps can resolve common inquiries instantly, and supply chain managers can monitor inventory levels, all without waiting for developers or AI specialists. Because agents are built visually and embedded into the Joget platform, organizations gain automation that's fast to deploy, easy to adapt, and always aligned with real business processes. The result? Teams move faster, reduce manual work, and stay in control, because every agent operates within workflows where humans set the rules and retain final say. One Platform. Multiple AI Innovations. Real Business Impact. Part of Joget Intelligence, AI Agent Builder joins three other powerful Joget AI tools: AI Designer (for building and refining apps and forms using natural language, documents, or images), AI Assistant (an in-app assistant for real-time guidance, smart recommendations, and data-driven insights), and AI Bundle (a suite of pre-built AI tools). Together, they bring practical, responsible AI into everyday business operations. "The companies that will thrive aren't just adopting AI, they're empowering their people to build with it. Joget AI Agent Builder is our answer to that shift: a platform where human insight leads, and AI executes," said Raveesh Dewan, President and CEO of Joget Inc. Julian Khoo, CTO of Joget Inc., added: "What sets our approach apart is governance. These agents operate within structured, auditable workflows, with human-in-the-loop controls for critical decisions. You get autonomy without losing oversight, and speed without sacrificing responsibility." Enterprise-Ready Agentic AI That Fits Your Workflow The timing aligns with a major industry shift. According to Gartner, "By 2028, 33% of enterprise software applications will include agentic AI, up from less than 1% in 2024, with at least 15% of day-to-day work decisions being made autonomously through AI agents." With Joget AI Agent Builder, users can: Build in minutes: Visually design agents using drag-and-drop logic. Test confidently: Simulate real-world scenarios in a built-in preview environment. Integrate seamlessly: Embed agents directly into existing Joget applications. Stay in control: Ensure human approval for high-stakes actions. Whether automating routine approvals, resolving support tickets, or managing inventory alerts, Joget puts adaptable, goal-driven AI within reach of every team, delivering agentic AI with human oversight across HR, finance, IT, customer service, and beyond. Let Agentic AI Work for You, Today Learn more about Joget AI Agent Builder. For more in-depth insights on Joget AI Agent Builder, join the upcoming webinar: "From Idea to Your First AI Agent in Minutes — No Coding Required" – Register here Media Contact: pr@joget.com About Joget Joget offers an open-source, AI-powered platform that converges no-code/low-code development with AI to rapidly build and customize enterprise applications at scale. By combining AI with visual app builders—not raw code—Joget makes app generation faster, safer, and more accessible for business users and developers alike. With Generative AI and Agentic AI capabilities, Joget Intelligence enables organizations to automate and enhance processes while maintaining oversight and compliance. Unlike typical AI code generation, Joget's visual-first approach ensures applications are maintainable and governed within collaborative human workflows. As an Application and Integration Fabric, Joget connects legacy and modern systems seamlessly. Its extensible, open-source core and plugin architecture offer unmatched flexibility, and its White Label solution allows OEMs and digital solution providers to fully rebrand the platform. Trusted by startups, global enterprises, and government agencies, Joget delivers the speed of AI with the control of visual development for scalable, intelligent digital transformation.Visit www.joget.com and follow us on LinkedIn, X, Facebook, or YouTube.
A12 藝術空間
#Application
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
